Heart defect-tongue hamartoma-polysyndactyly syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1338OMIM:217085Q87.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Heart defect-tongue hamartoma-polysyndactyly syndrome, also known as oral-facial-digital syndrome type IV (OFD IV) or Mohr-Majewski syndrome, is an extremely rare congenital malformation syndrome characterized by the combination of congenital heart defects, hamartomas (benign tumor-like growths) of the tongue, and polysyndactyly (extra digits that may also be fused together). This condition affects multiple body systems including the cardiovascular system, the oral cavity, and the skeletal system, particularly the hands and feet. Additional features may include other oral findings such as lobulated tongue, lingual nodules, and cleft palate or lip, as well as various limb anomalies including tibial dysplasia and short limbs. The condition is present at birth and is typically recognized in the neonatal period based on the characteristic combination of physical findings. Congenital heart defects associated with this syndrome can vary in type and severity. The skeletal abnormalities, particularly polysyndactyly, are among the most recognizable features. Some patients may also exhibit facial dysmorphism and central nervous system anomalies. Treatment is symptomatic and supportive, as there is no cure for the underlying condition. Management typically involves a multidisciplinary approach including cardiac surgery or intervention for significant heart defects, surgical correction of polysyndactyly and other limb anomalies, and removal of tongue hamartomas if they interfere with feeding or breathing. Prognosis depends largely on the severity of the cardiac and other organ involvement. Genetic counseling is recommended for affected families.

Also known as:

Clinical phenotype terms— hover any for plain English:

2-3 finger cutaneous syndactylyHP:0001233Subvalvular aortic stenosisHP:0001682Hamartoma of tongueHP:0011802Benign neoplasm of the central nervous systemHP:0100835
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Heart defect-tongue hamartoma-polysyndactyly syndrome.

View clinical trials →

No actively recruiting trials found for Heart defect-tongue hamartoma-polysyndactyly syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Heart defect-tongue hamartoma-polysyndactyly syndrome community →

No specialists are currently listed for Heart defect-tongue hamartoma-polysyndactyly syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Heart defect-tongue hamartoma-polysyndactyly syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Heart defect-tongue hamartoma-polysyndactyly syndromeForum →

No community posts yet. Be the first to share your experience with Heart defect-tongue hamartoma-polysyndactyly syndrome.

Start the conversation →

Latest news about Heart defect-tongue hamartoma-polysyndactyly syndrome

No recent news articles for Heart defect-tongue hamartoma-polysyndactyly syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Heart defect-tongue hamartoma-polysyndactyly syndrome

What is Heart defect-tongue hamartoma-polysyndactyly syndrome?

Heart defect-tongue hamartoma-polysyndactyly syndrome, also known as oral-facial-digital syndrome type IV (OFD IV) or Mohr-Majewski syndrome, is an extremely rare congenital malformation syndrome characterized by the combination of congenital heart defects, hamartomas (benign tumor-like growths) of the tongue, and polysyndactyly (extra digits that may also be fused together). This condition affects multiple body systems including the cardiovascular system, the oral cavity, and the skeletal system, particularly the hands and feet. Additional features may include other oral findings such as lobu

How is Heart defect-tongue hamartoma-polysyndactyly syndrome inherited?

Heart defect-tongue hamartoma-polysyndactyly syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Heart defect-tongue hamartoma-polysyndactyly syndrome typically begin?

Typical onset of Heart defect-tongue hamartoma-polysyndactyly syndrome is neonatal. Age of onset can vary across affected individuals.